Healthpeak Properties Inc experienced a price increase of 4.67%, reaching a 20-day high. This movement comes amid broader market strength, with the Nasdaq-100 up 0.19% and the S&P 500 up 0.12%.
The surge is attributed to Healthpeak's announcement of a monthly cash dividend of $0.10167 per share for the first quarter of 2026, reflecting strong cash flow and profitability. This dividend declaration, along with a stable dividend policy, enhances investor confidence and positions Healthpeak favorably within the S&P 500 as a leading real estate investment trust.
This positive development not only attracts long-term investors but also strengthens Healthpeak's market presence, potentially driving future capital growth and reinforcing its competitive edge in the REIT sector.
Wall Street analysts forecast DOC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DOC is 19.23 USD with a low forecast of 16.71 USD and a high forecast of 21.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
Wall Street analysts forecast DOC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DOC is 19.23 USD with a low forecast of 16.71 USD and a high forecast of 21.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
6 Hold
0 Sell
Moderate Buy
Current: 17.150
Low
16.71
Averages
19.23
High
21.00
Current: 17.150
Low
16.71
Averages
19.23
High
21.00
Wells Fargo
John Kilichowski
Equal Weight
maintain
$18 -> $19
2025-11-25
Reason
Wells Fargo
John Kilichowski
Price Target
$18 -> $19
AI Analysis
2025-11-25
maintain
Equal Weight
Reason
Wells Fargo analyst John Kilichowski raised the firm's price target on Healthpeak Properties to $19 from $18 and keeps an Equal Weight rating on the shares. The firm says that despite a few high-profile exceptions, most REITs delivered Q3 2025 earnings and outlooks reflecting healthy operating conditions despite macro and labor market concerns.
Baird
Wesley Golladay
Outperform -> Outperform
downgrade
$21 -> $20
2025-11-12
Reason
Baird
Wesley Golladay
Price Target
$21 -> $20
2025-11-12
downgrade
Outperform -> Outperform
Reason
Baird analyst Wesley Golladay lowered the firm's price target on Healthpeak Properties to $20 from $21 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for DOC
Unlock Now
Cantor Fitzgerald
Neutral
initiated
$20
2025-10-01
Reason
Cantor Fitzgerald
Price Target
$20
2025-10-01
initiated
Neutral
Reason
Cantor Fitzgerald initiated coverage of Healthpeak Properties with a Neutral rating and $20 price target. The firm initiated coverage of the U.S. REITs, including nine property sectors and 40 stocks. Although there isn't widespread enthusiasm for a REIT recovery in 2026 just yet, Cantor believes the industry could be well-positioned over the next 12 to 24 months, the analyst tells investors in a research note. The firm's top property sector calls include Office, Industrial, Healthcare and Net Lease, but is incrementally more cautious on Multifamily and Hotels.
Raymond James
Jonathan Hughes
Market Perform -> Outperform
upgrade
$20
2025-09-15
Reason
Raymond James
Jonathan Hughes
Price Target
$20
2025-09-15
upgrade
Market Perform -> Outperform
Reason
Raymond James analyst Jonathan Hughes upgraded Healthpeak Properties to Outperform from Market Perform with a $20 price target. The firm cites the stock's recent underperformance relative to peers, driven by a large Q2 occupancy decline in the life science segment, and expectations for limited downside to life science fundamentals going forward for the upgrade. Healthpeak shares trade at an attractive valuation given its \"well-covered\" 6.7% dividend yield, the analyst tells investors in a research note.
About DOC
Healthpeak Properties, Inc. is a fully integrated real estate investment trust (REIT). The Company acquires, develops, owns, leases, and manages healthcare real estate across the United States. It owns, operates, and develops real estate focused on healthcare discovery and delivery. The Company’s segments include Lab, Outpatient medical and continuing care retirement community (CCRC). The Outpatient medical segment owns, operates, and develops outpatient medical buildings, hospitals, and lab buildings. The lab segment properties contain laboratory and office space, are leased primarily to biotechnology, medical device and pharmaceutical companies, scientific research institutions, government agencies, and other organizations involved in the life science industry. Its CCRC segment is a retirement community that include independent living, assisted living, memory care, and skilled nursing units to provide a continuum of care in an integrated campus.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
